3 days ago
Teva 2024 Healthy Future Report: Access to Medicines Programs
Access to Medicines ProgramsIn 2020, we committed to launching eight Access to Medicines programs by 2025, aimed at providing treatments to underserved populations worldwide via customized, localized models conducted with partner organizations, and tailored to meet specific national health challenges.
Having launched two new access programs in 2024 (El Salvador and Strategic Emergency Stockpile), we surpassed our goal a year early, with a total of nine programs launched: four programs are eligible for inclusion in our product volume sustainability-linked bond (SLB) target.
Our programs consist of product donations or social business programs, and each supports global health needs by reaching undeserved communities.
Increasing Regulatory Submissions In LMICsIn addition to the efforts previously mentioned, to enhance access to medicines to underserved populations, our International Market Region supports our access efforts to increase regulatory submissions of WHO EML products across key therapeutic areas, in LMIC, in line with our SLB target. Between 2022 and 2024 we filed 74 submissions and, in January 2025, we achieved our target of 75 submissions.
1 Worth of medicine provided is represented in wholesale acquisition cost (WAC) or the local market equivalent.
Other Access to Medicines initiatives
In addition to our nine strategic access programs, we continuously explore other opportunities to support underserved patients and those facing emergencies and disasters, so they can obtain the medicines they need. In 2024, our progress included:
Addressing Emergencies and DisastersWe reinforced our longstanding commitment to support patients in need during emergencies and disasters through our strategic partnerships and timely interventions. By leveraging our extensive network of credible suppliers and partners, we serve as a trusted collaborator with healthcare organizations to address urgent medical needs.
For example, during hurricanes Milton and Helene, Teva donated over 1.5 million doses of products including medications indicated in diabetes, CVD, respiratory diseases, diarrhea, epilepsy and infectious diseases.
Additionally, we introduced our new Strategic Emergency Stockpile (SES) program, working with Direct Relief to provide products to support disaster relief efforts worldwide.
'Sustainability linked bond' (SLB) indicates program eligible to the SLb target. 1 Worth of medicine provided is represented in wholesale acquisition cost (WAC) or the local market equivalent. 2 Teva Cares Foundation is a separate legal entity funded by Teva.
Our Nine Access Programs
In 2024, we launched two new Access Programs:
Below we outline progress during 2024 for our previously launched programs:
Note: 'Sustainability-linked bond' (SLB) indicates program eligible to the SLB target. 1 Worth of medicine provided is represented in wholesale acquisition cost (WAC) or the local market equivalent.
To learn more, read the full 2024 Healthy Future the full 2024 Healthy Future Report Disclosures.
Visit 3BL Media to see more multimedia and stories from Teva Pharmaceutical
